Skip to main content

Table 1 Myelodysplastic syndrome disease characteristics of patients treated with ezatiostat and analyzed by Illumina expression arrays

From: Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome

Baseline Cytopenia

Illumina #

Response

Sex

Age

Hgb

WBC

ANC

Platelets

WHO

IPSS

Blasts (%)

Karyotype

E only

TLK-1

NR

F

69

9.3

4.4

3.08

325

RARS

Int-1

1

46,XX,del(11)(q14q23)[11]/46,XX[9]

E only

TLK-10

NR

F

84

7.7

3.7

2.07

324

RAEB-2

Int-1

10

NA

E only

TLK-11

NR

M

53

11

9.7

7,00

310

RA

Int-1

2

47,XY[19]

E only

TLK-12

NR

M

81

8.9

4..1

2.10

343

RA

Low

1

45,X,-Y[4]/46,XY[16]

EN

TLK-13

NR

F

72

10

1.6

0.58

113

RAEB-1

Int-1

6

46,XX[19]

P only

TLK-14

NR

M

76

12

1.7

1.27

94

RA

Low

1

45,X,-Y[19]

E only

TLK-15

NR

F

67

6.2

1.8

1.08

133

RA

Low

3-5

46,XX[19]

NP

TLK-16

NR

F

68

12.2

3.2

1.05

73

RA

Low

<5

46,XX[19]

EN

TLK-2

NR

M

67

10

2.8

1.232

120

RA

Int-1

1

46,XY[20]

EP

TLK-21

NR

M

63

10

3.2

0.64

76

RA

Int-1

<5

46,XY[19]

E only

TLK-27

NR

F

73

9.2

4.6

3.22

221

RARS

Int-1

0-1

46,XX,der(7)t(1;7)(q25;36) ort(1;7)(q23;q32)[5]/46,Xdel(X)(q24q28),der(7)t(1;7)(q25;q36) ort(1;7)(q23;q32)[15]

N only

TLK-28

NR

M

67

14

3.2

0.99

108

RARS

NA

NA

46,XY[19]

ENP

TLK-29

NR

F

74

10.8

3.7

1.27

56

RA

Int-1

1

46,XX,dup(1)(q21q42)[16]/46,XX[4]

E only

TLK-3

NR

M

71

8.9

2.1

1.39

108

RA

Low

0-1

46,XY[19]

EP

TLK-30

NR

M

79

10

3.17

3.36

101

RA

Low

1

46,XY,del(20)(q11.2q13.3)[19]

P only

TLK-4

NR

M

77

13

3.3

2.25

93

RA

Int-1

0

46,XY-20,+/der(20)del(20)(p12)del(20) (q11.2)[21]

E only

TLK-5

NR

M

81

7.8

10.8

7.88

157

RARS

Low

2

46,XY,del(2)(p13),inv(5)(q13q33),add(13)(q22)[7]/46,XY,del(5)(q13q33)[3],/add(13)(q22)[3]/46,XY[10]

E only

TLK-6

NR

M

73

10

3.9

3

289

RA

Low

1

46,XY[20]

E only

TLK-7

NR

F

67

11

8.3

3.74

251

RARS

Int-1

1-2

47,XX,+8[14]/46,XX[6]

NP

TLK-8

NR

M

75

12

2.9

1.22

104

RA

Int-1

1

44,XY,del(3)(p12p21),-5-9,add(13)(p11.2)[5]/44,X,-Y,del(3)(p12p21),del(5)(q13q33),add (6)(q21),-9,-12,add(13)(p11.2),+mar[2]/43,sdl118 [2]/43,sdl2,add(7)(q22)[6]/46,XY[5]

E only

TLK-9

NR

M

77

9.1

4

2.6

253

RARS

Low

1

46,XY[19]

ENP

TLK-17

R

F

66

8.7

2

0.34

90

RARS

Int1

3

46,XX[19]

E only

TLK-18

R

M

80

9.3

2.7

1.9

168

RA

Low

4

46,XY[19]

ENP

TLK-19

R

M

79

10

3.3..

0.79

98

RAEB-1

Int-1

4

46,XY,t(2;3)(p15;q27)[11]/46,XY [9]

EN

TLK-20

R

M

68

9.7

2.8

0.67

336

RARS

Low

2

46,XY[19]

P only

TLK-22

R

M

71

11

5.64

3.38

35

RA

Low

1

46,XY[19]

NP

TLK-23

R

F

71

13

2.6

1.48

106

RA

Int-1

0-1

46,XX,-9,del(11)(q13),+mar[22]/46,XX[2]

EP

TLK-24

R

M

81

9.2

5.6

3.02

148

RA

Low

1

45,X,-Y[11]/46,XY[9]

EP

TLK-25

R

M

79

11

3.7

1

68

RAEB-1

Int-1

5

46,XY[19]

NP

TLK-26

R

F

75

13

3.6

1.26

39

RA

Low

3

46,XX[19]

  1. Abbreviations: ANC absolute neutrophil count, E erythroid, F female, Hgb hemoglobin, Int-1 International-1, IPSS International Prognostic Scoring System, M male, N neutrophil, NR nonresponder, P platelet, R responder, RA refractory anemia, RAEB-1 refractory anemia with excess blasts type 1, RAEB-2 RA with excess blasts type 2, RARS refractory anemia with ringed sideroblasts, WBC white blood count, WHO World Health Organization.